Published 11 May 2012
The concept of pre-exposure prophylaxis (PrEP) is a new HIV prevention method and is based on using antiretroviral treatments, used until now to treat infected people, to reduce the risk of HIV infection among non-infected people when they engage in sexual intercourse.
The French National AIDS Council (CNS) was asked by the Director General of Health to assess the benefits of promoting this new prevention strategy. The Council set out to produce a precise inventory of knowledge and debate raised by PrEP, explore the various issues and repercussions on HIV/AIDS prevention measures and formulate preliminary guidelines providing a framework for using PrEP in France.
PrEP is not a universal prevention method aimed at the general population. Its prevention benefits apply to those most at risk of contracting HIV. PrEP must be part of a comprehensive approach combining promotion of different prevention methods, screening and different use of therapies. It widens the range of available methods and highlights the need to promote combined prevention in order to offer a tailored response to individual situations and needs.
The CNS wishes to publish this opinion today, at a time when the US Food and Drug Administration (FDA), following recommendations made by a committee of experts and made public on 10th May 2012, is about to approve a supplemental New Drug Application (sNDA) for an antiretroviral treatment to be used for PrEP (Truvada® made by Gilead Sciences).
The CNS study has clarified the advantages of PrEP, potential target groups and the challenges that the prevention system must meet in order to optimally roll out PrEP in the French context.
You can also find on this website :
the Summary of the Opinion in pdf format
the complete Opinion
Contacts:
Julien Bressy: +33 (0)1 40 56 68 52 | +33 (0)6 83 56 15 34 | julien.bressy@sante.gouv.fr
Michel Celse: +33 (0) 1 40 56 68 56 | +33 (0)6 80 73 87 64 | michel.celse@sante.gouv.fr

L’ouvrage retrace la réflexion sur le VIH qui eut lieu dans les années 1990, pendant lesquelles l’auteur fut la première Présidente (de 1989 à 1995) du Conseil national du sida (...) | Published 23 May 2013
En clôture de la consultation organisée les 11 et 12 mars 2013 par l’IAS, l’ANRS et Sidaction, Patrick Yeni a présenté le point de vue du CNS sur les perspectives en matière de TaSP (...) | Published 17 April 2013
Retrouvez l’Avis, le Rapport, le Communiqué de presse et le programme de la réunion d’information et de débat du CNS consacrés aux autotests (...) | Published 22 March 2013
Le CNS a organisé une réunion d’information et de débat le vendredi 22 mars 2013, au Ministère des Affaires sociales et de la Santé (...) | Published 11 March 2013
4ème de couverture : "Ce neuvième rapport d’activité du Conseil national du sida couvre les années 2010-2011. Il s’inscrit à la fois dans la continuité des avis antérieurs du Conseil, mais aussi dans la volonté ferme de voir les politiques publiques s’infléchir (...) | Published 18 December 2012